

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problems Mailbox.**

**THIS PAGE BLANK (USPTO)**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>5</sup> : C07C 233/36, C12N 5/00</p>	<p>A1</p>	<p>(11) International Publication Number: WO 94/05624 (43) International Publication Date: 17 March 1994 (17.03.94)</p>
<p>(21) International Application Number: PCT/US93/08130 (22) International Filing Date: 27 August 1993 (27.08.93) (30) Priority data: 07/937,508 28 August 1992 (28.08.92) US (71) Applicant: LIFE TECHNOLOGIES, INC. [US/US]; 8717 Grovemont Circle, Gaithersburg, MD 20877 (US). (72) Inventors: GEBEYEHU, Gulilat ; 9512 Hale Place, Silver Spring, MD 20910 (US). JESSEE, Joel, A. ; 4139 Old National Road, Mt. Airey, MD 21771 (US). CICC- RONE, Valentina, C. ; 11044 Rutledge Drive, Gaithers- burg, MD 20878 (US). HAWLEY-NELSON, Pamela ; 10112 Stoneybrook Drive, Silver Spring, MD 20910 (US). CHYTIL, Anna ; 1503 Erin Lane, Nashville, TN 37221 (US).</p>		<p>(74) Agents: GREENLEE, Lorange, L. et al.; Greenlee and Winner, 5370 Manhattan Circle, Suite 201, Boulder, CO 80303 (US). (81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i></p>
<p>(54) Title: CATIONIC LIPIDS  (57) Abstract  The present invention discloses cationic lipids useful for making lipid aggregates for delivery of macromolecules and other compounds into cells. They are especially useful for the DNA-dependent transformation of cells. Also disclosed are lipids useful both for the delivery of macromolecules and also useful as intermediates for making other such lipids.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TC	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

## CATIONIC LIPIDS

### Field of the Invention

Cationic lipid compounds are disclosed, having utility in lipid aggregates for delivery of macromolecules and other compounds into cells.


### Background of the Invention

Lipid aggregates such as liposomes have been found to be useful as agents for delivery to introduce macromolecules, such as DNA, RNA, protein, and small chemical compounds such as pharmaceuticals, to cells. In particular, lipid aggregates comprising cationic lipid components have been shown to be especially effective for delivering anionic molecules to cells. In part, the effectiveness of cationic lipids is thought to result from enhanced affinity for cells, many of which bear a net negative charge. Also in part, the net positive charge on lipid aggregates comprising a cationic lipid enables the aggregate to

bind polyanions, such as nucleic acids. Lipid aggregates containing DNA are known to be effective agents for efficient transfection of target cells.

The structure of various types of lipid aggregates varies, depending on composition and method of forming the aggregate. Such aggregates include liposomes, unilamellar vesicles, multilamellar vesicles, micelles and the like, having particle sizes in the nanometer to micrometer range. Methods of making lipid aggregates are by now well-known in the art. The main drawback to use of conventional phospholipid-containing liposomes for delivery is that the material to be delivered must be encapsulated and the liposome composition has a net negative charge which is not attracted to the negatively charged cell surface. By combining cationic lipid compounds with a phospholipid, positively charged vesicles and other types of lipid aggregates can bind DNA, which is negatively charged, can be taken up by target cells, and can transfect target cells. (Felgner, P.L. et al. (1987) Proc. Natl. Acad. Sci. USA 84:7413-7417; Eppstein, D. et al., U.S. Patent 4,897,355.)



A well-known cationic lipid disclosed in the prior art is N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA). The structure of DOTMA is:




DOTMA by itself or in 1:1 combination with dioleoylphosphatidyl-ethanolamine (DOPE) is formulated into liposomes using standard techniques. Felgner, et al. supra demonstrated that such liposomes provided efficient delivery of nucleic acids to some types of cells. A DOTMA:DOPE (1:1) formulation is sold under the tradename LIPOFECTIN (Gibco/BRL: Life Technologies, Inc., Gaithersburg, MD). Another commercially available cationic lipid is 1,2-bis(oleoyloxy)-3-(trimethylammonia) propane (DOTAP), which differs from DOTMA only in that the oleoyl moieties are linked via ester, rather than ether bonds to the propylamine. DOTAP is believed to be more readily degraded by target cells. A related group of prior art compounds differ from DOTMA and DOTAP in that one of the methyl groups of the trimethylammonium group is replaced by a hydroxyethyl group. Compounds of this type are similar to the Rosenthal Inhibitor (RI) of phospholipase A (Rosenthal, A.F. and Geyer, R.P. (1960) J. Biol. Chem. 235:2202-2206) which has stearoyl esters linked to the propylamine core. The dioleoyl analogs of RI are commonly abbreviated as DORI-ether and DORI-ester, depending on the linkage of the fatty acid moieties to the propylamine core. The hydroxy group can be used as a site for further functionalization, for example by esterification to carboxyspermine.

Another class of prior art compounds has been disclosed by Behr et al. (1989) Proc. Natl. Acad. Sci. USA 86:6982-6986; EPO publication 0 394 111 (Oct. 24, 1990), in which carboxyspermine

has been conjugated to two types of lipids. The structures of 5-carboxyspermylglycine dioctadecylamide (DOGS) is:




The structure of dipalmitoylphosphatidylethanolamine 5-carboxyspermylamide (DPPES) is:



Both DOGS and DPPES have been used to coat plasmids, forming a lipid aggregate complex that provides efficient transfection. The compounds are claimed to be more efficient and less toxic than DOTMA for transfection of some cell lines. DOGS is available commercially as TRANSFECTAM™ (Promega, Madison, WI).

A cationic cholesterol derivative (DC-Chol) has been synthesized and formulated into liposomes in combination with DOPE. (Gao, X. and Huang, L. (1991) Biochim. Biophys. Res. Comm. 179:280-285) The compound's structure is





5

Liposomes formulated with DC-Chol are said to provide more efficient transfection and lower toxicity than DOTMA-containing liposomes for some cell lines.


10 Lipopolylysine, formed by conjugating polylysine to DOPE, has been reported to be especially effective for transfection in the presence of serum, a condition likely to be encountered in vivo (Zhou, X. et al. (1991) Biochim. Biophys. Acta 1065:8-14).

15 Despite advances in the field, a need remains for a variety of improved cationic lipid compounds. In particular, no single cationic lipid to date has been found to work well with all cell types. Since different cell types differ from one another in membrane composition, it is not surprising that different compositions and types of lipid aggregate are effective for different cell types, either for their ability to contact and  
20 fuse with target cell membranes, or for aspects of the transfer process itself. At present these processes are not well understood, consequently the design of effective cationic lipids is largely empirical. Besides content and transfer, other factors are of importance, for example, ability to form lipid  
25 aggregates suited to the intended purpose, toxicity to the target cell, stability as a carrier for the compound to be delivered, and ability to function in an in vivo environment. In addition,

lipid aggregates can be improved by broadening the range of substances which can be delivered to cells. The cationic lipid compounds of the present invention have improved function with respect to several of the foregoing attributes.

## 5 Summary of the Invention

The present invention provides novel cationic lipids according to the general formula:



wherein  $R_1$  and  $R_2$  separately or together are  $C_{1-23}$  alkyl or

or  $-\overset{\overset{O}{\parallel}}{C}-C_{1-23}$  alkyl or alkenyl,  $q$  is 1 to 6,

$Z_1$  and  $Z_2$  separately or together are H or unbranched alkyl

$C_{1-6}$


$X_1$  is  $-(CH_2)_nBr, Cl, F$  or  $I$   $n=0-6$  or



$X_2$  is  $-(CH_2)_nNH_2$   $n=0-6$  or

$X_3$  is  $-NH-(CH_2)_m-NH_2$   $m=2-6$  or

$X_4$  is  $-NH-(CH_2)_3-NH-(CH_2)_4-NH_2$  or

$X_5$  is  $-NH-(CH_2)_3-NH-(CH_2)_4-NH(CH_2)_3-NH_2$





where p is 2-5, Y is H or other groups attached by amide or alkyl amino group or

$X_9$  is a polyamine, e.g., polylysine, polyarginine, polybrene, histone or protamine or

$X_{10}$  is a reporter molecule, e.g.,  $\begin{array}{c} \text{O} \\ \parallel \\ \text{-NH-C-fluorescein, biotin,} \\ \text{folic acid or PPD, or} \end{array}$

$X_{11}$  is a polysaccharide or substituted polysaccharide, or

$X_{12}$  is a protein or

$X_{13}$  is an antibody or

$X_{14}$  is an amine or halide reactive group or

$X_{15}$  is  $\text{-(CH}_2\text{)}_r\text{-SH}$  where r is 0-6 or

$X_{16}$  is  $\text{-(CH}_2\text{)}_s\text{-S-S-(CH}_2\text{)}_t\text{-NH}_2$  where s is 0-6 and t is 2-6.

Compounds of the invention are useful, either alone or in combination with other lipid aggregate-forming components, e.g., DOPE or cholesterol, for formulation into liposomes or other lipid aggregates. Such aggregates are cationic, able to complex with anionic macromolecules, such as nucleic acids. The lipid aggregate macromolecular complex interacts with cells making the

macromolecule available for absorption and uptake by the cell. The halogenated compounds of the invention are also especially useful as intermediates for chemically coupling the cationic lipid to reporter molecules, proteins, polypeptides, antibodies, polysaccharides and the like to permit targeted delivery, quantitative assessment of targeting, greater efficiency of delivery and enhanced range of delivery capabilities.

Compounds of the invention can conjugate to a variety of useful molecules and substances such as polyamines, polyamine acids, polypeptides, proteins, fluorescent dyes, intercalating dyes, reporter molecules, biotin, polysaccharides, monosaccharides, solid support materials, magnetic beads, dendrimer particles, DEAE-Sephadex<sup>TM</sup> (Pharmacia, Inc.), and the like. Depending on the specific compound of the invention and the substance to be conjugated thereto, conjugation can occur using a compound of the invention as an alkylating agent, using a free amine thereof to react with an amine-reactive group of the substance to be conjugated, or by the use of cross-linking agents.

#### Brief Description of the Figures

Figure 1 is a diagrammatic reaction scheme for synthesis of cationic lipids of the invention. Numerals identify the specific numbered compounds described in the Examples.

Figure 2 is a diagrammatic reaction scheme for conjugating a halogenated compound of the invention ( $X=X_1$ ) to molecules having an amino functionality ( $W$ ).

Figure 3 is a diagrammatic reaction scheme for conjugating  
5 a compound of the invention (e.g.,  $X = X_2 - X_8$ ) to a molecule or substance having an amine-reactive group ( $W_2$ ).

Figure 4 is a diagrammatic reaction scheme for conjugating a compound of the invention (e.g.,  $X = X_2 - X_8$ ) to another molecule or substance by use of a cross-linking agent.

10 Detailed Description of the Invention

The present invention provides novel cationic lipids of the DORI family, however, they provide unique properties and advantages not heretofore available to the liposome art. The compounds can be used alone or in combination with other  
15 compounds, for example, DOPE, to prepare liposomes and other lipid aggregates suitable for transfection or delivery of compounds other than DNA to target cells, either in vitro or in vivo.

Compounds of the invention having a halogen substituent ( $X$   
20 is  $X_1$ ) are additionally useful for synthesis of more complex cationic lipids having the halogen replaced by a desired compound. The convenience of the halogen as a useful leaving group makes such substitutions straightforward. Examples of

useful substituents include, without limitation, reporter groups, proteins, peptides, antibodies, carbohydrates, polysaccharides, and the like. Reporter groups can be any readily analyzed or visualized molecule, including, without limitation, fluorescent tags (Fluorescein, rhodamine), luminescent tags (4-methoxy-4-(3-phosphatephenyl)-spiro[1,2-dioxetane-3,2'-adamantane] (PPD)) biotin, dyes, chelators, affinity probes, etc. Such reporters enable visualization and measurement of target cell-lipid aggregate interactions. Such reporters also provide a means for subsequently accessing targeted cells, by providing surface binding sites unique to targeted cells. In addition, certain drugs and therapeutic compounds can be substituted at the halogen site, by a metabolizable linkage, thereby enhancing efficiency of drug delivery. Also, DNA intercalating compounds can be substituted, providing further DNA binding and enhancing transfection efficiency.

Compounds of the invention having an amide linked carboxyspermine ( $X=X_6$ ), lysine ( $X=X_8$ ) and shorter diamino acids ( $X=X_7$ ) are especially efficient DNA delivery compounds, and can be used to form lipid aggregates by themselves, without combination with DOPE or other liposome-forming compound.

Compounds of the invention having the cationic lipid component coupled to a carbohydrate or polysaccharide ( $X=X_{11}$ ), a polypeptide or protein ( $X=X_{12}$ ) or an antibody ( $X=X_{13}$ ) are useful in applications where the function of the substituent group is important. For example, specific delivery to a selected target

cell type can be facilitated by a cationic lipid of the invention having a substituent that binds an antigen or receptor specific to the desired target cell. The ability to address a selected target cell type is especially useful in in vivo applications, for example in gene therapy.

Compounds of the invention wherein the cationic lipid component comprises enol-ether linkages are susceptible to hydrolysis in an acidic environment. These compounds, which are structurally similar to the plasmalogens found in cell membranes, are useful in pH-controlled delivery of macromolecules. In enol-ether compounds,  $R_1$  and  $R_2$  are alkenyl groups having a double bond adjacent to the ether linkage, and X is hydrogen or  $X_1 - X_{16}$ .

### Definitions

Lipid Aggregate is a generic term which includes liposomes of all types both unilamellar and multilamellar as well as micelles and more amorphous aggregates of cationic lipid or lipid mixed with amphipathic lipids such as phospholipids.

Target Cell refers to any cell to which a desired compound is delivered, using a lipid aggregate as carrier for the desired compound.

Transfection is used herein to mean the delivery of expressible nucleic acid to a target cell, such that the target cell is rendered capable of expressing said nucleic acid. It

will be understood that the term "nucleic acid" includes both DNA and RNA without regard to molecular weight, and the term "expression" means any manifestation of the functional presence of the nucleic acid within the cell, including without  
5 limitation, both transient expression and stable expression.

Delivery is used to denote a process by which a desired compound is transferred to a target cell such that the desired compound is ultimately located inside the target cell or in, or on the target cell membrane. In many uses of the compounds of  
10 the invention, the desired compound is not readily taken up by the target cell and delivery via lipid aggregates is a means for getting the desired compound into the cell. In certain uses, especially under in vivo conditions, delivery to a specific target cell type is preferable and can be facilitated by  
15 compounds of the invention.

The cationic lipids were prepared by following the general reaction scheme given below (Fig. 1).

3-dimethylamino-1,2-propanediol was treated with an alkali base followed with an alkylating agent of the desired length to  
20 obtain the corresponding dialkoxy derivative. To obtain the acyl derivatives the diol was treated with the desired acyl chloride in pyridine. Thus compound 1 was obtained by treating 3-dimethylamino-1,2-propanediol with oleyl mesylate in the presence of KOH in refluxing xylene.



Compound 1 was further alkylated using dibromoethane at high temperature to give compound 3. Treatment of compound 3 with diaminopropane or spermine at high temperature yielded compound 4 or compound 5, respectively.

5 Alkylation of compound 1 at 130°C with 2-bromoethyl phthalimide yielded compound 7. Removal of the phthalimido group with hydrazine yielded compound 2. Compound 2 was acylated with tetra-*t*-butoxycarbonylspermine-carboxylic acid in the presence of dicyclohexylcarbodiimide to obtain compound 6. Removal of the  
10 BOC protecting group of compound 6 with trifluoroacetic acid resulted in compound 8.

The scheme provides a general method for the conjugation of lipids to any molecule or substance of interest. The alkylbromide 3 can be used as a general alkylating agent. Thus,  
15 any molecule of interest that has a nucleophilic moiety can react with compound 3 (Fig. 2) (J. March (1985) Advanced Organic Chemistry, John Wiley & Sons, New York, pp. 364-366; Hilgetag & A. Martini, eds. (1972) Preparative Organic Chemistry, John Wiley & Sons, New York, pp. 448-460). For example, the primary amino  
20 group of polylysine reacts with the bromide to give polylysine-lipid-conjugate. Other macromolecules that contain amino groups such as proteins and antibodies can also be conjugated to lipids in this manner. Smaller molecules that contain amino groups such as intercalators (methidium spermine), fluorescent dyes,  
25 nucleotides, nucleosides, amino acids, peptides and other

reporter molecules such as biotin can also be conjugated in this manner.

Conversely, compounds 2, 4, 5, or 8 can be used for the conjugation of any molecules of interest that have electrophilic or nucleophilic sites. Compounds 2, 4, 5, or 8 can react with reporter molecules or other desired molecules if these molecules contain carboxylic acid sites, NHS ester or other active groups such as isothiocyanates, alkylhalides or chlorotriazines (Fig. 3) (Keezer, F. and Douraghi-Zdeh, K. (1967) Chem. Rev. 67:107; Dottario-Martin, B. and Ravel, J.H. (1978) Anal. Biochem. 76:562; Staros, J.V. (1982) Biochemistry 21:3950.

Compounds 2, 4, 5, or 8 can also be conjugated with molecules that contain nucleophilic sites such as amines by using cross-linking agents (Fig. 4). Disuccinimidyl suberate can be used to conjugate compounds 2, 4, 5, or 8 to molecules that contain an amino group (Staros, J.V. (1982) Biochemistry 21:3990). Cross-linking agents that contain NHS ester and maleimide can be used to conjugate compounds 2, 4, 5, or 8 to molecules that contain sulfhydryl group (Fig. 4) (Ji, T.H. (1979) Biochem. Biophys. Acta 559:39).

The compounds of the invention can be used in the same manner as are prior art compounds such as DOTMA, DOTAP, DOGS and the like. Methods for incorporating such cationic lipids into lipid aggregates are well-known in the art. Representative methods are disclosed by Felgner et al., supra; Epstein et al.

supra; Behr et al. supra; Bangham, A. et al. (1965) M. Mol. Biol. 23:238-252; Olson, F. et al. (1979) Biochim. Biophys. Acta 557:9-23; Szoka, F. et al. (1978) Proc. Natl. Acad. Sci. USA 75:4194-4198; Mayhew, E. et al. (1984) Biochim. Biophys. Acta 775:169-175; Kim, S. et al. (1983) Biochim. Biophys. Acta 728:339-348; and Fukunaga, M. et al. (1984) Endocrinol. 115:757-761. Commonly used techniques for preparing lipid aggregates of appropriate size for use as delivery vehicles include sonication and freeze-thaw plus extrusion. See, e.g., Mayer, L. et al. (1986) Biochim. Biophys. Acta 858:161-168. Microfluidization is used when consistently small (50 - 200 nm) and relatively uniform aggregates are desired (Mayhew, E., supra). Aggregates ranging from about 50 nm to about 200 nm diameter are preferred; however, both larger and smaller sized aggregates are functional.

Methods of transfection and delivery of other compounds are well-known in the art. The compounds of the present invention yield lipid aggregates that can be used in the same processes as those prior art compounds.

A one-to-one mixture (by weight) of the desired lipid and dioleoylphosphatidyl ethanolamine was prepared in  $\text{CHCl}_3$ . The  $\text{CHCl}_3$  was removed on the rotary evaporator to obtain a thin film of lipid mixture. The mixture was hydrated with enough water to obtain approximately 1.25 mg of lipid per ml of solution. The solution was passed through a microfluidizer twice and diluted to 1 mg/ml. The liposome formulation was then filtered through

a 0.2  $\mu$  filter. Compound 8 was also formulated without DOPE either by sonication at 1 mg/ml in water or by dissolving a dried lipid film with ethanol and then adding water to give a final concentration of 2.5 mg/ml. Ethanol was 10% of that volume. In some instances, this was further diluted with water to 1 mg/ml, 4% ethanol.

The use of representative compounds of the invention is further detailed by reference to the following Examples. In each case, the ability of various compounds of the invention to provide efficient transfection was compared with a control using Lipofectin<sup>TM</sup> reagent. All abbreviations used herein are standard abbreviations in the art. Specific procedures not described in detail are either referenced or well-known in the art.

## EXAMPLES

### Example 1

2,3-dioleyloxy-1-(N,N-dimethylamino)propane (1). To a three-necked, 2-liter round bottom flask equipped with a Dean-Stork trap were added 3-dimethylamino-1,2-propanediol (6.08 g, 51.1 mmol), xylene (1300 ml) and KOH (8.0 g). The solution was refluxed for 2 hours while removing water azeotropically via the Dean-Stork trap. Oleyl mesylate (40.0 g, 115.6 mmol) in 100 ml xylene was added to the reaction mixture drop-wise in 30 minutes. Refluxing was continued for 3 hours and the reaction mixture

concentrated to a gum. The gum was triturated with 400 ml hexane and filtered. The solid was washed with 100 ml hexane followed with 200 ml ethyl acetate. The filtrates were combined, concentrated and subjected to flash chromatography. 2,3-dioleyloxy-1-(N,N-dimethylamino)propane was obtained as a colorless oil in 76% yield, TLC:  $R_f$  = 0.37 (Silica gel: 5% EtOAc: hexane); IR: 2925, 2850, 1469, 1120, 1040  $\text{cm}^{-1}$ ; HNMR ( $\text{CDCl}_3$ )  $\delta$  5.35 (t, 4H), 4.13 (q, 1H) 3.4-3.65 (m, 6H), 2.35-2.45 (m, 2H), 2.25 (s, 6H), 1.95-2.05 (m, 8H), 1.5-1.65 (m, 4H), 1.2-1.45 (m, 4H) 0.9 (t, 6H).

#### Example 2

2H-Isoindole-2-ethanaminium, N-[2,3-bis(9-octadecenyloxy)-propyl]-1,3-dihydro-N,N-dimethyl-1,3-dioxo-, bromide (7). 2,3-dioleyloxy-1-(N,N-dimethylamino)propane (1.238 g, 2 mmole) was combined with N-(2-bromoethyl)phthalimide and heated under argon (130°C) for 18 hours. TLC analysis (Silica gel 20% MeOH/ $\text{CHCl}_3$ ) showed the lipid starting material was completely consumed. The desired material was purified by flash chromatography using step gradient of hexane/ $\text{CHCl}_3$  (1:1), to 20% MeOH/ $\text{CHCl}_3$ . The desired material was obtained in 25% yield as a gum. IR: 2920, 2850, 1760(s), 1720, 1460, 1390  $\text{cm}^{-1}$ .

#### Example 3

1-Propanaminium, N-(2-amino)ethyl-N,N-dimethyl-2,3-bis(9-octadecenyloxy)-bromide (2). Compound 7 (800 mg) was

combined with hydrazine (200  $\mu$ l) in MeOH (30 ml). The reaction mixture was refluxed under argon for 20 hours. The reaction mixture was cooled and the precipitate was filtered off. The filtrate was concentrated to dryness. The desired product was  
5 obtained after reverse phase chromatography (C-18, 20% aqueous methanol) in 48% yield. IR: 3300, 2920, 2850, 1460  $\text{cm}^{-1}$ .

#### Example 4

3-Oxa-5,9,15-triazaheptadecan-17-aminium, N-[2,3-bis(9-octa-  
decenyloxy)propyl]-9-[(1,1-dimethylethoxy)carbonyl]-13-{[(1,1-di-  
10 methylethoxy)carbonyl][3-{[(1,1-dimethylethoxy)-carbon-  
yl]amino}propyl]amino}-N,N,2,2-tetramethyl-4,14-dioxo-,  
bromide (6). N,N,N,N-tetra-t-butoxy-5-spermine carboxylic acid  
(470 mg, 0.7 mmoles) was treated with dicyclohexylcarbodiimide  
(206 mg, 1 mmole) and N-hydroxy succinimide (115 mg, 1 mmole) in  
15 50 ml of 1:1 dioxane: $\text{CH}_2\text{Cl}_2$ . The reaction mixture was stirred at  
room temperature overnight under argon. The dicyclohexyl urea  
that precipitated was filtered off. Compound 2 (220 mg) was  
dissolved in  $\text{CH}_2\text{Cl}_2$  (10 ml) that contained triethylamine (24  $\mu$ l)  
and added to the reaction mixture. The mixture was stirred at  
20 room temperature overnight. The solution was concentrated to  
dryness and taken in 100 ml  $\text{CHCl}_3$  and extracted with 0.1 M  $\text{NaHCO}_3$   
(2 x 100 ml) followed with  $\text{H}_2\text{O}$  (100 ml). The  $\text{CHCl}_3$  layer was  
dried over  $\text{Na}_2\text{SO}_4$  and concentrated. The desired material was  
obtained in 53% yield after flash chromatography.  $R_f$  = 0.8  
25 (20% MeOH in  $\text{CHCl}_3$ ) IR: 2920, 2850, 1680, 1375, 1175  $\text{cm}^{-1}$ .

Example 5

1-Propanaminium, N-[2-[[2,5-bis[(3-aminopropyl)amino]-1-oxo-  
pentyl]amino]ethyl]-n,n-dimethyl-2,3,-bis(9-octadecenyloxy)-,  
tetra(trifluoroacetate) salt (8). A solution of compound 6 in  
5  $\text{CH}_2\text{Cl}_2$  (160 mg in 2 ml) was treated with 2 ml of trifluoroacetic  
acid/ $\text{CH}_2\text{Cl}_2$  (1:1) at room temperature for 15 minutes. The mixture  
was then concentrated to dryness and co-evaporated with methanol  
(3 x 30 ml). The desired product was obtained in 68% yield after  
reverse phase chromatography (C-18, 20% aqueous methanol eluent).  
10 IR: 1920, 2850, 1680, 1210, 1140,  $\text{cm}^{-1}$ .

Example 6

1-Propanaminium, N-[2-(2-bromo)ethyl]-N,N-dimethyl-  
2,3-bis(9-octadecenyloxy)-, bromide (3). 2,3-dioleyloxy-  
1-(N,N-dimethylamino)propane (1.8 g) was dissolved in 9 ml of  
15 dibromoethane (that was passed through an alumina (III) column).  
The solution was heated at 80°C for 8 hours and concentrated in  
vacuo to a gum. The gum was dissolved in minimum amount (~60 ml)  
hot  $\text{CH}_3\text{CN}$  and cooled to -20°C overnight. The yellowish  
precipitate was separated by decantation. The precipitate was  
20 dissolved in  $\text{CH}_2\text{Cl}_2$  (120 ml) and decolonized with neutral norite.  
The  $\text{CH}_2\text{Cl}_2$  was evaporated and the residue was crystallized from  
 $\text{CH}_3\text{CN}$  as above to obtain the desired material in 43% yield.

Example 7

1-Propanaminium, N-{2-[[3-[[4-[(3-aminopropyl)amino]butyl]-  
amino]propyl]amino]ethyl}-n,n-dimethyl-2,3-bis-(9-octadecenyl-  
oxy)-, bromide (5). Compound 3 (1.2 g) was treated with 3 ml of  
5 spermine at 80°C for 2 days under argon. The reaction mixture  
was concentrated under vacuum at high temperature (50°C). The  
mixture was co-evaporated with water (50 ml) followed with  
ethanol (50 ml) and used in transfection without further  
purification.

10 Example 8

1-Propanaminium, N-[2-[(3-aminopropyl)amino]ethyl]-N,N-di-  
methyl-2,3-bis(9-octadecenyl-oxy)-, bromide (4). Compound 3  
(460 mg) was heated at 60°C in 3 ml diaminopropane under Argon  
for 3 hours. The mixture was concentrated to dryness at 50°C  
15 under vacuum. The gummy material that was obtained was  
co-evaporated with water (50 ml) followed with ethanol (50 ml).  
The material was used in transfection without further  
purification.

Example 9

20 Cell culture and plasmids. Baby hamster kidney (BHK-21),  
COS-7, HeLa-S3 cells, and normal human fibroblasts isolated from  
newborn foreskin dermis were grown in Dulbecco's-modified Eagle's  
medium (DMEM) containing 10% fetal bovine serum (FBS), 2 mM



L-glutamine (gln), 0.1 mM MEM nonessential amino acids (NEAA), 100 U/ml penicillin, and 100 µg/ml streptomycin. NIH-3T3 cells were grown in DMEM containing 10% calf serum (CS), 2 mM gln, 0.1 mM NEAA 100 U/ml penicillin, and 100 µg/ml streptomycin. PC12 cells were grown in DMEM containing 10% horse serum, 5% FBS, 2 mM gln, 0.1 mM NEAA, 100 U/ml penicillin, and 100 µg/ml streptomycin. Jurkat cells (human lymphoid cell line) were grown in RPMI-1640 supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin. Human keratinocytes were isolated from newborn foreskin epidermis and cultured in Keratinocyte Growth Medium (Clonetics, San Diego, CA). All cell lines were maintained in a humidified incubator with a 5% CO<sub>2</sub> atmosphere at 37°C.

pSV2CAT (5.0 Kb) was described previously (Gorman, C.M. et al. (1982) Mol. Cell. Biol. 2:1044). pCMVCAT (5.0 Kb) was also described previously (Foeking M.K. and Hofstetter, H. (1986) Gene 45:101). Plasmid DNA was purified by isopycnic centrifugation in CsCl/EtBr gradients after recovery by alkaline lysis (Maniatis, T. et al. (1982) in Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, pp. 90-91).

#### Example 10

Transient transfection of adherent cells (BHK-21, HeLa-S3, NIH-3T3, PC12, Cos-7, human keratinocytes, human fibroblasts) with cationic lipids. For transient transfection of pSV2CAT DNA

or pCMVCAT DNA, cells were plated in 6-well tissue culture dishes (35 mm wells) and incubated overnight to approximately 60% confluency. To transfect cells in one well, 1-2  $\mu$ g of pSV2CAT DNA or pCMVCAT DNA was diluted in 100  $\mu$ l Opti-MEM I. Cationic lipids were diluted separately in another 100  $\mu$ l aliquot of Opti-MEM I. The two solutions were then mixed in a polystyrene tube, incubated for 10-15 min at room temperature to allow the formation of a DNA-liposome complex, and diluted to one ml by adding 0.8 ml Opti-MEM I or DMEM containing 5% fetal bovine serum (FBS), 2 mM gln, 0.1 mM NEAA, and lacking antibiotics. The cells were washed once with Opti-MEM I or serum-free DMEM, and the DNA-liposome complex was added directly to the cells. After a six hr incubation at 37°C, the transfection complexes were removed and two ml of DMEM containing 10% FBS, 2 mM gln, 0.2 mM NEAA, 100 U/ml penicillin, and 100  $\mu$ g/ml streptomycin, was added to each well. Note: human keratinocytes were cultured and transfected in Keratinocyte Growth Medium. Cells were incubated for an additional 48 hrs and lysed in situ by freeze-thawing once or twice in 300  $\mu$ l 0.1M Tris-HCl, pH 7.8-8.0, containing 0.1% Triton X-100. Cell lysates were assayed for CAT activity.

### Example 11

#### Transient Transfection of Jurkat Cells with Cationic Lipids.

For transient nuclear expression of pSV2CAT or pCMVCAT in Jurkat cells, cells were washed with Opti-MEM I or serum-free RPMI 1640 containing 2 mM gln and plated in six-well plates at a density of  $3 \times 10^6$  cells per well in 0.8 ml Opti-MEM I or RPMI 1640. For

each transfection, 5  $\mu$ g pSV2CAT DNA or 2 $\mu$ g pCMVCAT DNA was diluted in 100  $\mu$ l Opti-MEM I. Lipids were diluted separately in another 100 $\mu$ l aliquot of Opti-MEM I. The two solutions were then mixed in a polystyrene tube and incubated for 10-15 min at room temperature. The DNA-liposome complex was added to the cell suspensions and incubated 6 hours at 37°C, after which 4 ml growth medium were added per well (RPMI-1640; 10% FBS). Phorbol myristate acetate (Sigma Chemical Co., St. Louis, MO) and phytohemagglutinin (Sigma) were also added to a final concentration of 50 ng/ml and 1  $\mu$ g/ml, respectively, to activate the cells. Cells were harvested at approximately 48 hours post-transfection by centrifugation. Cell lysates were prepared by resuspending cell pellets at 0°C in 0.1 M Tris-HCl pH 8.0 containing 0.1% Triton X-100 and freeze-thawing once. Cell lysates were cleared by centrifugation and assayed for CAT activity.

#### Example 12

Chloramphenicol acetyltransferase (CAT) assay. Cell lysates were assayed for CAT activity as described by Neumann et al. (1987) BioTechniques 5:444 using [ $^{14}$ C]-butyryl coenzyme A (New England Nuclear, Boston, MA). The enzyme reactions were incubated for 2 hrs at 37°C, overlaid with 3.0 ml Econofluor (New England Nuclear) and then incubated for an additional 2 hrs to allow diffusion of the acetylated chloramphenicol into the scintillation fluid. CAT activity was determined by measuring radioactivity in a liquid scintillation counter.

Example 13

Results. Results are shown in Tables 1-8. The "% protein" column indicates the relative amount of protein in the sample tested for CAT activity and therefore provides a way to estimate toxicity of the compounds being tested. The "CAT Activity" column indicates the relative transfection effectiveness of the lipid formulation in the various cell lines. The control sample was a cell culture grown under similar conditions as those that were transfected, but with no DNA or cationic lipid added. Protein was measured using a commercially available Bradford protein assay (BioRad Laboratories, Richmond, CA).

For BHK-21 (Table 1), NIH-3T3 (Table 2B), keratinocytes (Table 3), PC12 (Table 4), Jurkat (Table 5), and Cos-7 (Table 6) cells, compound 8 was highly effective for DNA transfection with minimal toxicity. Fibroblasts (Table 7) were also successfully transfected with compound 8. Compounds 4 and 5 were also effective for DNA transfection in keratinocytes (Table 3), and compound 3 had good activity in HeLa-S3 cells in the presence or absense of serum (Table 8). Compounds 2 and 3 also had good activity for DNA transfection in NIH-3T3 cells (Tables 2A and 2B).

TABLE 1

## TRANSFECTION RESULTS WITH BHK-21 CELLS

5	LIPID	CAT ACTIVITY (CPM)	$\mu$ g LIPID	% protein (% of control)
	COMPOUND 2/DOPE	12202	3 $\mu$ g	57
10	COMPOUND 3/DOPE	11,226	6 $\mu$ g	29
	COMPOUND 8/DOPE	73,628	6 $\mu$ g	83
15	COMPOUND 8/DOPE	49,417	18 $\mu$ g	103
	COMPOUND 8 (EtOH)	67,858	3.8 $\mu$ g	59
	COMPOUND 8 SONICATED	73,856	6 $\mu$ g	114

20 Transfections were for 6 hours in OPTI-MEM I with 1  $\mu$ g pSV2CAT DNA, in 35 mm wells. 3  $\mu$ l of 300  $\mu$ l extract assayed for CAT activity.

26

TABLE 2A

NIH-3T3 (Mouse fibroblast cell line)

5	LIPID	CAT ACTIVITY (CPM)	$\mu$ g LIPID	% protein (% of control)
	COMPOUND 4	3,114	24 $\mu$ g	111%
10	COMPOUND 5/DOPE	1,180	26 $\mu$ g	92%
	COMPOUND 3	6,074	16 $\mu$ g	35%

15 Transfections for 6 hours in OPTI MEM serum-free medium with 2 $\mu$ g pSV2CAT DNA.

TABLE 2B

NIH-3T3 (MOUSE FIBROBLAST CELL LINE)

20	LIPID	CAT ACTIVITY (CPM/150ul)	$\mu$ g LIPID	% protein (% of control)
	COMPOUND 8/DOPE	17,564	12 $\mu$ g	100%
25	COMPOUND 8	30,488	15 $\mu$ g	89%
	COMPOUND 2/DOPE	14,890	12 $\mu$ g	68%
30	COMPOUND 3/DOPE	13,002	18 $\mu$ g	55%
	COMPOUND 4/DOPE	1,446	18 $\mu$ g	104%

DNA-Lipid complexes made in OPTI-MEM. Transfections for 6 hours in DMEM with 2 $\mu$ g pCMVCAT DNA.

27

TABLE 3

## NORMAL HUMAN KERATINOCYTES

5	LIPID	CAT ACTIVITY (CPM)	$\mu$ g LIPID	% protein (% of control)
	COMPOUND 4	20,038	40 $\mu$ g	41%
10	COMPOUND 5/DOPE	17,818	90 $\mu$ g	39%
	COMPOUND 3	10,598	10 $\mu$ g	42%
15	COMPOUND 8 (EtOH)	33,818	25 $\mu$ g	38%
	COMPOUND 8/DOPE	20,410	25 $\mu$ g	65%

20 Transfections for 5 hours (compound 8) or 6 hours (compounds 3, 4, and 5) with 2 $\mu$ g pSV2CAT DNA in 35 mm well. 50  $\mu$ l of 300 $\mu$ l assayed for CAT activity.

TABLE 4

TRANSFECTION RESULTS WITH PC12 CELLS  
(RAT PHEOCHROMOCYTOMA CELL LINE)

25	LIPID	CAT ACTIVITY (CPM/150ul)	$\mu$ g LIPID	% protein (% of control)
30	COMPOUND 8/DOPE	12,950	15 $\mu$ g	87%
	COMPOUND 8	28,512	40 $\mu$ g	66%

35 DNA-lipid complexes were made in OPTI-MEM. PC12 cells ( $6 \times 10^5$  cells) were transfected in DMEM with 2 $\mu$ g of pCMVCAT DNA for 6 hours.

28

TABLE 5A

TRANSFECTION RESULTS WITH JURKAT CELLS  
(HUMAN T-LYMPHOMA CELL LINE) WITH pSV2CAT

5	LIPID	CAT ACTIVITY (CPM/150 $\mu$ l)	$\mu$ g LIPID	% protein (% of control)
10	COMPOUND 4	2252	20 $\mu$ g	93%
	COMPOUND 5	1170	20 $\mu$ g	100%
	COMPOUND 4	820	30 $\mu$ g	100%
15	COMPOUND 5/DOPE	702	30 $\mu$ g	76%
	COMPOUND 3	3008	30 $\mu$ g	97%

20 Jurkat cells ( $3 \times 10^6$  cells) were transfected in OPTI-MEM with 5 $\mu$ g of pSV2CAT DNA for 6 hours.

TABLE 5B

TRANSFECTION RESULTS WITH JURKAT CELLS  
(HUMAN T-LYMPHOMA CELL LINE) WITH pCMVCAT

25	LIPID	CAT ACTIVITY (CPM/150 $\mu$ l)	$\mu$ g LIPID	% protein (% of control)
30	COMPOUND 8/DOPE	12,766	30 $\mu$ g	113%
	COMPOUND 8	44,996	15 $\mu$ g	47%

35 DNA-lipid complexes were made in OPTI-MEM. Jurkat cells ( $3 \times 10^6$  cells) were transfected in RPMI-1640 with 2 $\mu$ g of pCMVCAT DNA for 6 hours.



29

TABLE 6  
COS-7 CELLS

5	LIPID	CAT ACTIVITY (CPM/150ul)	$\mu$ g LIPID	% protein (% of control)
	COMPOUND 8	14,282	12 $\mu$ g	99.1%
10	COMPOUND 8 DOPE	53,875	6 $\mu$ g	68.9%

DNA-lipid complexes were made in DMEM. Cos-7 cells ( $1 \times 10^5$  cells) were transfected in DMEM with 1  $\mu$ g of pSV2CAT DNA for 6 hours.

15

TABLE 7

TRANSFECTION RESULTS WITH NORMAL HUMAN FIBROBLASTS

20	LIPID	CAT ACTIVITY (CPM)	$\mu$ g LIPID	% protein (% of control)
	COMPOUND 8 (EtOH)	4,288	6 $\mu$ g	56
25	COMPOUND 8/DOPE	11,486	18 $\mu$ g	18

Transfection for 6 hours in OptiMEM I with 2  $\mu$  pSV2CAT DNA. 150  $\mu$ l of 300  $\mu$ l extract assayed for CAT activity.

TABLE 8


TRANSFECTION OF HeLa-S3 CELLS BY COMPOUND 3

5	MEDIUM	CAT ACTIVITY (CPM)	$\mu$ g LIPID	% protein (% of control)
	DMEM, 5% FBS	78,798	6 $\mu$ g	54%
10	OPTIMEM I, 0% FBS	29,400	12 $\mu$ g	43%

Transfections for 6 hours with 2 $\mu$ g pSV2CAT DNA.

## WE CLAIM:

1. A composition having the structure



wherein  $R_1$  and  $R_2$ , independently of one another, are  $C_{1-23}$  alkyl or

alkenyl, or  $-\overset{\overset{O}{\parallel}}{C}-C_{1-23}$  alkyl or alkenyl,  $Z_1$  and  $Z_2$ , independently of one another, are H or unbranched alkyl  $C_{1-6}$ ,  $q$  is 1 to 6,  $X$  is selected from any of  $X_1-X_{14}$  where

$X_1$  is  $-(CH_2)_nBr$ ,  $(CH_2)_nCl$ ,  $(CH_2)_nF$  or  $(CH_2)_nI$  where  $n=0-6$  or

$X_2$  is  $-(CH_2)_nNH_2$   $n=0-6$  or


$X_3$  is  $-NH-(CH_2)_m-NH_2$   $m=2-6$  or

$X_4$  is  $-NH-(CH_2)_3-NH-(CH_2)_4-NH_2$  or

$X_5$  is  $-NH-(CH_2)_3-NH-(CH_2)_4-NH(CH_2)_3-NH_2$  or

$X_6$  is  $-NH-\overset{\overset{O}{\parallel}}{C}-CH-(CH_2)_3NH(CH_2)_3-NH_2$   
 $|$   
 $NH-(CH_2)_3NH_2$

$X_7$  is  $-NH-\overset{\overset{O}{\parallel}}{C}-CH-(CH_2)_3NH_2$   
 $|$   
 $NH_2$  or



where p is 2-5, Y is H or

$X_{15}$  is  $\text{-(CH}_2\text{)}_r\text{-SH}$  where r is 0-6 or

$X_{16}$  is  $\text{-(CH}_2\text{)}_s\text{-S-S-(CH}_2\text{)}_t\text{-NH}_2$  where s is 0-6 and t is 2-6.

2. A compound according to claim 1 wherein X is  $X_2$ .

10 3. A compound according to claim 1 wherein X is  $X_2$ , and n is 2.

4. A compound according to claim 1 wherein X is  $X_2$ , n is 1,  $R_1 = R_2$  is  $C_{18}$  alkenyl and  $Z_1 = Z_2$  is methyl.

5. A compound according to claim 1 wherein X is  $X_1$ .


15 6. A compound according to claim 1 wherein X is  $X_1$  is  $(CH_2)_nBr$  where n is 1.

7. A compound according to claim 1 wherein X is  $X_1$  is  $(CH_2)_nBr$  where n is 1,  $R_1 = R_2$  is  $C_{18}$  alkenyl and  $Z_1 = Z_2$  is methyl.

8. A compound according to claim 1 wherein X is  $X_3$ .

9. A compound according to claim 1 wherein X is  $X_3$ , q is 2, and m is 3.

10. A compound according to claim 1 wherein X is  $X_3$ , q is 2, m is 3,  $Z_1 = Z_2$  is methyl and  $R_1 = R_2$  is  $C_{18}$  alkenyl.
11. A compound according to claim 1 wherein X is  $X_5$ .
12. A compound according to claim 1 wherein X is  $X_5$  and q is 2.
- 5 13. A compound according to claim 1 wherein X is  $X_5$ , q is 2,  $Z_1 = Z_2$  is methyl, and  $R_1 = R_2$  is  $C_{18}$  alkenyl.
14. A compound according to claim 1 wherein X is  $X_6$ .
15. A compound according to claim 1 wherein X is  $X_6$  and q is 2.
16. A compound according to claim 1 wherein X is  $X_6$ , q is 2,  $Z_1 = Z_2$  is methyl and  $R_1 = R_2$  is  $C_{18}$  alkenyl.
- 10 17. A lipid aggregate comprising a compound of claim 1.
18. A method of conjugating a cationic lipid to a substance having a free amino group comprising alkylating said substance with a cationic lipid having the structure



wherein  $R_1$  and  $R_2$  separately or together are  $C_{1-23}$  alkyl or


alkenyl, or  $\begin{array}{c} \text{O} \\ \parallel \\ -\text{C}-\text{C}_{1-23} \end{array}$  alkyl or alkenyl,  $Z_1$  and  $Z_2$  separated or together are H or unbranched alkyl  $\text{C}_{1-6}$ ,  $q$  is 1 or 2,  $X$  is selected from any of  $X_1-X_{14}$  where

$X_1$  is  $(\text{CH}_2)_n\text{Br}$ ,  $(\text{CH}_2)_n\text{Cl}$ ,  $(\text{CH}_2)_n\text{F}$  or  $(\text{CH}_2)_n\text{I}$  where  $n=0-6$ .

19. A method according to claim 18 wherein the alkylating agent is a cationic lipid wherein  $X_1$  is  $(\text{CH}_2)_n\text{Br}$ .

20. A method according to claim 18 wherein the alkylating agent is a cationic lipid wherein  $X_1$  is  $(\text{CH}_2)_n\text{Br}$  and  $n = 1$ .

21. A method of conjugating a cationic lipid to a substance having an amino-reactive group comprising reacting said substance with a cationic lipid having the structure





wherein  $\text{R}_1$  and  $\text{R}_2$ , independently of one another, are  $\text{C}_{1-23}$  alkyl or

alkenyl, or  $\begin{array}{c} \text{O} \\ \parallel \\ -\text{C}-\text{C}_{1-23} \end{array}$  alkyl or alkenyl,  $Z_1$  and  $Z_2$ , independently of one another, are H or unbranched alkyl  $\text{C}_{1-6}$ ,  $q$  is 1 to 6,  $X$  is selected from any of  $X_2-X_7$  where


35

- $X_2$  is  $(CH_2)_nNH_2$   $n=0-6$  or  
 $X_3$  is  $-NH-(CH_2)_m-NH_2$   $m=2-6$  or  
 $X_4$  is  $-NH-(CH_2)_3-NH-(CH_2)_4-NH_2$  or  
 $X_5$  is  $-NH-(CH_2)_3-NH-(CH_2)_4-NH(CH_2)_3-NH_2$  or



22. A method according to claim 21 wherein the amino-reactive group is an NHS ester, a carboxyl, an isothiocyanate, an aldehyde or a chlorotriazine.

23. A method of conjugating a cationic lipid to a substance having a reactive group comprising reacting a cross-linking reagent with said lipid and said substance, whereby a conjugate is formed, said cationic lipid having the structure





wherein  $R_1$  and  $R_2$ , independently of one another, are  $C_{1-23}$  alkyl or


alkenyl, or  $\begin{array}{c} \text{O} \\ \parallel \\ -C-C_{1-23} \end{array}$  alkyl or alkenyl,  $Z_1$  and  $Z_2$ , independently of one another, are H or unbranched alkyl  $C_{1-6}$ ,  $q$  is 1 or 2,  $X$  is selected from any of  $X_2-X_7$  where

36

- $X_2$  is  $(CH_2)_nNH_2$   $n=0-6$  or  
 $X_3$  is  $-NH-(CH_2)_m-NH_2$   $m=2-6$  or  
 $X_4$  is  $-NH-(CH_2)_3-NH-(CH_2)_4-NH_2$  or  
 $X_5$  is  $-NH-(CH_2)_3-NH-(CH_2)_4-NH(CH_2)_3-NH_2$  or



24. The method of claim 23 wherein the crosslinking agent is a disuccinimidyl suberate, and the reactive group of the substance is an amino group.  
 25. The method of claim 23 wherein the crosslinking agent has an NHS ester group and a maleimide group, and the reactive group of the substrate is a sulfhydryl group.  
 26. A method of transfecting a cell comprising contacting said cell with a lipid aggregate comprising DNA and a cationic lipid composition having the structure



wherein  $R_1$  and  $R_2$ , independently of one another, are  $C_{1-23}$  alkyl or



alkenyl, or  $\text{-}\overset{\text{O}}{\parallel}\text{C-C}_{1-23}$  alkyl or alkenyl,  $Z_1$  and  $Z_2$ , independently of one another, are H or unbranched alkyl  $\text{C}_{1-6}$ ,  $q$  is 1 to 6,  $X$  is selected from any of  $X_1\text{-}X_{14}$  where

X<sub>1</sub> is -(CH<sub>2</sub>)<sub>n</sub>Br, (CH<sub>2</sub>)<sub>n</sub>Cl, (CH<sub>2</sub>)<sub>n</sub>F or (CH<sub>2</sub>)<sub>n</sub>I where n=0-6 or

$$X_2 \text{ is } -(\text{CH}_2)_n\text{NH}_2 \quad n=0-6 \text{ or}$$

$X_3$  is  $-NH-(CH_2)_m-NH_2$   $m=2-6$  or

$X_4$  is  $-\text{NH}-(\text{CH}_2)_3-\text{NH}-(\text{CH}_2)_4-\text{NH}_2$  or

X<sub>5</sub> is -NH-(CH<sub>2</sub>)<sub>3</sub>-NH-(CH<sub>2</sub>)<sub>4</sub>-NH(CH<sub>2</sub>)<sub>3</sub>-NH<sub>2</sub> or

$$X_6 \text{ is } \begin{array}{c} \text{O} \\ \parallel \\ \text{NH}-\text{C}-\text{CH}-(\text{CH}_2)_3\text{NH}(\text{CH}_2)_3\text{NH}_2 \\ | \\ \text{NH}-(\text{CH}_2)_3\text{NH}_2 \end{array}$$
$$\text{X}_7 \text{ is } \text{NH}-\overset{\text{O}}{\parallel}\text{C}-\underset{\text{NH}_2 \text{ or}}{\text{CH}}-(\text{CH}_2)_3\text{NH}_2$$
$$X_8 \text{ is } \begin{array}{c} \text{O} \\ \parallel \\ \text{-NH-C-CH-(CH}_2\text{)}_p\text{NH}_2 \\ | \\ \text{NH-Y} \end{array}$$

where p is 2-5, Y is H or

X<sub>15</sub> is -(CH<sub>2</sub>)<sub>r</sub>-SH where r is 0-6 or

$X_{16}$  is  $-(CH_2)_s-S-S-(CH_2)_t-NH_2$  where s is 0-6 and t is 2-6.

27. The method of claim 26 wherein the cationic lipid is compound 3.

28. The method of claim 26 wherein the cationic lipid is compound 4.


29. The method of claim 26 wherein the cationic lipid is compound 5.

5 30. The method of claim 26 wherein the cationic lipid is compound 8.



31. A kit for preparing a lipid aggregate comprising a cationic lipid according to claim 1.

1/4

## SCHEME 1



SUBSTITUTE SHEET

2 / 4  
SCHEME 2

R = POLYLYSINE

POLYAMINE ACID

POLYPEPTIDE

PROTEIN


FLUORESCENT DYES

INTERCALATORS

REPORTER MOLECULES



POLYAMINE

### SCHEME 3





4 / 4

## SCHEME 4



R = POLYLYSINE  
 POLYAMINE ACID  
 POLYPEPTIDE  
 PROTEIN  
 FLUORESCENT DYES  
 INTERCALATORS  
 REPORTER MOLECULES  
 POLYAMINE



R = POLYPEPTIDE  
 PROTEIN  
 FLUORESCENT DYES  
 INTERCALATORS  
 REPORTER MOLECULES

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US93/08130

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) : C07C 233/36; C12N 5/00

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 206/569; 435/71; 436/172.3; 554/105, 106, 107; 560/222, 251; 564/197, 292, 504

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE STRUCTURE SEARCH

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US, A, 4,897,355 (EPPSTEIN ET AL) 30 JANUARY 1990.	1-31
A	US, A, 4,889,953 (INOUE ET AL) 26 DECEMBER 1989.	1-25

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:	T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be part of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

18 OCTOBER 1993

Date of mailing of the international search report

NOV 15 1993

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Authorized officer

RICHARD RAYMOND TCE

Facsimile No. NOT APPLICABLE

Telephone No. (703) 308-1235

**THIS PAGE BLANK (USPTO)**